Zymeworks

company

ZYME NYSE ISIN US98985Y1082 SEC CIK 1937653 LEI 894500AHOYAGYLYZJL67
Follow Zymeworks Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $256.5M +828.7% vs same quarter last year
Net income $173.7M +986.1% vs same quarter last year
EPS, diluted $2.28 +976.9% vs same quarter last year
Operating cash flow −$24M +23.5% vs same quarter last year
Revenue by quarter
$31M
$27.1M
$48.7M
$27.6M
$2.5M
$2.4M
$4.6M
$256.5M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400M$600MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$106M−$81.1M
FY24$76.3M−$122.7M
FY23$76M−$118.7M
FY22$412.5M$124.3M
FY21$26.7M−$211.8M
FY20$39M−$180.6M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1000%−750%−500%−250%0%250%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−87.3%−76.6%
FY24−179.7%−160.8%
FY23−181.6%−156.1%
FY2231.6%30.1%
FY21−808.2%−794%
FY20−481.3%−463.5%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100M$200MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$34.5M
FY24−$112M
FY23−$120.8M
FY22$136M
FY21−$204.9M
FY20−$155.7M
FY19-
Returned to shareholdersDividends paid and shares bought back
$0$20M$40M$60MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25$41.7M
FY24$30.1M
FY23$0
FY22$0
FY21-
FY20-
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Zymeworks
  • Healthcare median
−1000%−750%−500%−250%0%250%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearZymeworksHealthcare median
FY25−76.6%−30.6%
FY24−160.8%−47%
FY23−156.1%−58%
FY2230.1%−80.4%
FY21−794%−71.9%
FY20−463.5%−62.2%
FY19-−46.3%